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OBJECTIVES 
 
The management of the patient with peripheral arterial disease (PAD) has to be 
planned in the context of the natural history of the disease and considering, in particular, 
patient´s quality of life. The growing awareness and demand from the patients led to 
increased resource consumption. The cost benefit and resource consumption associated 
to the procedures is also to be accounted, maintaining or achieving better results, mainly 
shortening inpatient times and increasing treatment availability. 
This study analyses the outcomes of iliac stenting in TASC type D aortoiliac 
disease and compares its technical and short-term success to those of ABF grafting. The 
post-operative health-related quality of life (QoL) and walking ability in a sample of 
patients from two Portuguese hospitals (Centro Hospitalar de São João – CHSJ, and 
Centro Hospitalar do Tâmega e Sousa - CHTS) were acquired. Resorting to specialized 
software HVITAL the economic burden of both procedures in CHSJ was evaluated.  
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ABCTRACT PORTUGUESE 
 
Introdução: O tratamento da doença aorto-ilíaca oclusiva é uma das discussões mais 
significantes da cirurgia vascular. Nos últimos anos a abordagem endovascular tem 
demonstrado resultados promissores, contudo a cirurgia aberta mantém-se como o 
padrão de tratamento em lesões complexas. O objetivo deste estudo foi comparar os 
resultados técnicos, clínicos e económicos destas abordagens em doentes com padrão de 
doença TASC D no setor ilíaco. 
Métodos: Foram selecionados todos os doentes com padrão de doença TASC D no 
setor ilíaco submetidos a cirurgia de revascularização, aberta ou endovascular, de duas 
instituições portuguesas entre Janeiro de 2011 e Outubro de 2017. A seleção da 
abordagem foi deixada ao cirurgião.  
Resultados: O bypass aortobifemoral foi realizado como opção primária em 27 
doentes, e a abordagem endovascular foi tentada em 32 doentes. Os doentes submetidos 
a procedimentos endovasculares tinham maior probabilidade de apresentar insuficiência 
cardíaca (P=0.001) e história de tabagismo (P=0.030). O período médio de seguimento 
foi 56 ± 3.5 meses. A cirurgia aberta apresentou maior sucesso técnico (P=0.001); 
contudo, as taxas de salvamento de membro e de patência foram diferentes entre os 
grupos. A abordagem endovascular demonstrou associação com tempos de 
internamento mais curso, quer em enfermaria (6 vs 9 dias; P=0.041), em unidade de 
cuidados intensivos (0 vs 3.81 days; P=0.001) e com um custo por procedimento similar 
(µ: 2080 vs 1053€; P=0.6). Não foram detetadas diferenças na qualidade de vida pós-
operatória. 
Conclusão: A abordagem endovascular primária é pelo menos equivalente do ponto de 
vista clinico à cirurgia de bypass aortobifemoral, apresentando melhores resultados 
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económicos. A abordagem endovascular primária pode ser uma opção válida nos 
doentes com TASC D do setor ilíaco.  
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ABCTRACT EN 
 
Introduction: One of the most significant current discussions in peripheral artery 
disease is the treatment of aortoiliac occlusive disease (AIOD). In the last few years, 
endovascular approaches have shown promising results, however open surgery remains 
the standard for more complex lesions. The aim of this study was to compare technical, 
clinical and economic outcomes between both approaches in aortoiliac TASC D 
patients.  
Methods: Patients undergoing revascularization for TASC D lesions, either 
endovascular or open surgery, from two Portuguese institutions between January 2011 
and October 2017 were included. The surgical technique was left to the surgeon 
discretion.  
Results: Twenty-seven patients underwent aortobifemoral bypass and thirty-two 
patients were submitted to endovascular repair. The patients undergoing endovascular 
procedure were more likely to present chronic heart failure (P=0.001) and less smoking 
habits (P=0.03). The mean follow-up period was 56 ± 3.5months. The open surgery 
presented a higher technical success (P=0.001); however, limb salvage and patency 
rates were not different between groups. Endovascular approach was associated with a 
shorter lenght of stay, both in ward (6 vs 9 days; P=0.041) and in ICU unit (0 vs 3.81 
days; P=0.001) and lower hospital expenses (8337€ vs 20.694,5€; P=0.001) with a 
similar procedure cost (µ: 2080 vs 1053€; P=0.6). No differences were found in post-
surgical quality-of-life. 
Conclusion: Endovascular approach is, at least, clinically equivalent to open surgery 
and has superior economic outcome. The “endovascular-first” approach can be a valid 
option for TASC type D lesions. 
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INTRODUCTION 
 
Revascularization is the method of choice for treating lifestyle limiting 
intermittent claudication or critical ischemia in patients with aortoiliac occlusive disease 
(AIOD). According to the TransAtlantic Inter-Society Consensus II (TASC II), type D 
lesions (TASC D) include infra-renal aortoiliac occlusions (AIOC), unilateral 
occlusions of common (CIA) and external iliac arteries (EIA) and bilateral occlusions of 
EIA (Figure 1) (1). The treatment of these complex AIOC has been matter of debate 
over the last years.  The most recent European Society of Cardiology guidelines for 
treatment of peripheral artery disease recommend an endovascular-first approach for 
AIOD in case of short occlusive lesions, long and/or bilateral lesions in patients with 
several comorbidities and when performed by an experienced team, if not precluding 
subsequent surgical options (2). Open surgery remains the method of choice for young 
patients, fit for surgery, with AIOC (2). However, aortobifemoral (ABF) grafting is 
associated with a 3 to 5% risk of operative mortality (3), an important perioperative 
morbidity and a delay in the return to normal routine (4-6).  
In the last few years, device development to overcome total occlusions and 
increasing expertise levels among vascular surgeons led to a more frequent utilization of 
endovascular approaches for AIOC (7, 8). Moreover, endovascular approaches have 
demonstrated remarkable results on the treatment of aortoiliac TASC type D lesions, 
despite a lesser primary patency (4, 6, 9, 10), with experienced centers  and the most 
recent guidelines proposing an “endovascular-first” approach (2, 8). This 
recommendation is based on the assumption that an unsuccessful endovascular attempt 
does not preclude subsequent ABF grafting (5, 11). Debate about the best strategies for 
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the management of TASC type D lesions continues, and further evidence for the best 
treatment in this group of patients is still needed.  
This study analyses the outcomes of iliac stenting in TASC type D aortoiliac 
disease and compares its technical and short-term success to those of ABF grafting. The 
post-operative health-related quality of life (QoL) and walking ability in a sample of 
patients from two Portuguese hospitals, as well as the economic burden of both 
procedures, were evaluated.  
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METHODS 
 
Patient selection and data collection 
 
All patients with TASC D aorto-iliac lesions submitted either to endovascular or 
aorto-bifemoral bypass between January 2011 and October 2017 in two hospitals from 
metropolitan region of Porto were retrospectively assessed (Centro Hospitalar de São 
João – tertiary center - and Hospital Padre Américo – primary hospital). Patients with 
common femoral artery obstructive disease or aotoiliac aneurismatic disease, were 
excluded. The study protocol was approved by the local Ethics Committee and is 
according to Helsinki declaration. 
Patient demographics, cardiovascular risk factors, clinical presentation, 
procedural and lesion-specific details, outcomes and complications were retrospectively 
obtained from detailed revision of the patient’s clinical records. Original arteriogram 
and angio-CT images were retrieved and reviewed by three independent and 
experienced Vascular surgeons (J.R.N., J.S. and J.V.). 
All data regarding patients and procedure were defined according to the Society 
for Vascular Surgery reporting standard for lower extremity ischemia (12). Symptoms 
of chronic lower extremity ischemia were classified according to Rutherford(13). 
Outcome data including peri-procedural complications, ankle-brachial index (ABI) 
evolution, morbidity, and mortality were collected.  
 
Interventions 
 
Surgical decision between these 2 procedures was not randomly assigned and 
was performed according to operator discretion. In the endovascular group, if 
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recanalization was not successful, the ABF procedure was an option in patients who 
presented technically failed percutaneous intervention. Technical success was defined as 
patency at 30 days post-procedure (14). Both groups were analyzed regarding the initial 
approach decision. The failed revascularizations group was separately analyzed.  
All endovascular procedures were performed by a vascular surgeon, either in an 
angiography suite or in a C-arm equipped operative room. Under local anesthesia, an 
ipsilateral or a contralateral approach with a 6-French introducer was used depending on 
the clinical situation.  
Balloon-expandable (BE) stents were preferentially used for more severely 
calcified lesions as well as lesions in the aortic bifurcation. Self-expandable stents were 
usually implanted when the distal EIA was affected. No covered stents were used in this 
study. The length of lesions was categorized according to the criteria of the TASC II 
document(2). After stent implantation, aspirin (100 mg/day) and clopidogrel (75 
mg/day) were prescribed for 3 months. After 3 months, aspirin (100 mg/day) was 
recommended for long term use. 
Direct aortoiliac bypass operations were performed in an operating room under 
general anesthesia via a transperitoneal approach and unilateral bypass procedures via a 
retroperitoneal approach under epidural anesthesia. Double woven graft was used for all 
the bilateral aortoiliac surgical reconstructions. After synthetic vascular graft 
implantation, aspirin (100 mg per day) or clopidogrel (75 mg per day) were prescribed 
lifelong. 
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Postoperative surveillance 
 
Post-operative surveillance of revascularizations consisted of clinical evaluation, 
Doppler ultrasound and noninvasive Doppler arterial study with ABI measurements, 
and was generally performed at 1, 6 and 12 months, followed by biannual or annual 
follow-up. Primary patency was defined as patency during the interval between primary 
intervention and repeated radiologic intervention whether to thrombosis, in-stent 
restenosis or any other procedure necessary to maintain permeability. Assisted primary 
patency was defined as patency during the interval between primary intervention and 
the time when the angioplasty/bypass occluded, independently of the number of re-
interventions necessary to maintain permeability. Secondary patency is the patency 
obtained with the use of an additional or secondary surgical or endovascular procedure 
after occlusion occurs (14). Loss of primary patency was defined as stenosis >50% in 
doppler ultrassound or a >0.14 decrease in the ABI or stent / bypass thrombosis. In 
these cases, patients underwent either computed tomography angiography or 
conventional digital subtraction arteriography. The indications for secondary 
intervention included clinical symptoms associated with loss of primary patency. 
 
Endpoints 
 
Primary endpoint was primary, assisted primary or secondary patency. 
Secondary endpoints were limb salvage, prosthesis infection, mortality, QoL and 
disease specific Qol impairment and procedure costs.  
 Two Portuguese-language validated questionnaires were cross-sectionally 
(November 2017) applied to the sample: a disease-specific questionnaire - the walking 
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impairment questionnaire -, and a generic quality of life (QoL) questionnaire - the EQ-
5D-5L® (15, 16). On a total of 47 patients that were alive, 36 answered the 
questionnaire, of the remaining 11 patients, 8 were not possible to establish contact and 
3 did not have the necessary cognitive function. The patients were personally 
interviewed after a brief form explanation (A.F).  
The Centro Hospitalar São João, EPE. exact resource (equipment and disposable 
material) consumption cost was assessed using HVITAL Software and extracted by the 
data manager (S.M.V.) (17). This analysis was not possible in Centro Hospitalar do 
Tamega e Sousa. The cost of the length-of-stay was calculated based on the institutional 
data provided. Per day, the inpatient cost in a standard ward is 537 € whereas in ICU is 
2940€. The total cost of an intervention was calculated by the formula: procedure cost 
plus length-of-stay (procedure cost + mean ward days x 537€ + UCI days x 2940).  
In first instance, both surgical groups were compared regarding the baseline 
characteristics. Patients submitted to endovascular approach and patients with technical 
success were compared regarding baseline characteristics. A baseline comparison 
between patients technically succeeded and those not succeeded was also made. 
 
Statistical Analysis 
 
Statistics were performed with SPSS 24.0. Baseline characteristics were 
compared using Chi-Square, Student t-test and Mann-Whitney categorical variables 
analysed by chi-square; continuous variables with normal distribution by t-test and 
skewed with Mann-Whitney.. Outcome variables were evaluated by log rank test and 
Cox regression for the dependent time variables. The mean follow-up times were 
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calculated by the reverse Kaplan-Meier method. The threshold for significance was set 
at 5%.  
Variables with clinical relevance included in multivariate analysis were those 
associated with primary patency loss in univariate analysis.  
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RESULTS 
 
Study sample 
 
This study included 59 patients, 32 (54%) in the endovascular groups and 27 
(46%) in the open surgery group. In the overall study population, patients selected for 
an endovascular procedure had a mean age of 65.6±12.2 years while those undergoing 
ABF had a mean age of 62.1±6.5 years (P=0.173). Detailed data on demographics are 
described in table I. Chronic heart failure (CHF) was present only in the endovascular 
group (31.3% vs 0; P=0.03). A trend for smoking habits (ABF - 100% vs Endovascular 
- 75%; p=0.05) and chronic kidney disease (7.4% vs 25%; P=0.073) was present. 
 
Surgical outcomes 
 
The median follow-up for all patients was 56±3.5 months and did not 
significantly differ between groups (mean: endovascular approach 48±5.3; ABF 
65.5±3.9, P=0.689). 
Technical success was significantly higher in the open surgery group (100% vs 
65.6%, P=0.001). Baseline comparison between groups revealed that lighter smoking 
habits (100% vs 75%, P=0.005) and CHF (0 vs 31.3%, P=0.001) at presentation were 
significantly more prevalent in the endovascular approach (Table 1). The group with 
endovascular technical success differed similarly from the ABF group although 
demonstrating additionally significance for chronic kidney disease (CKD - 
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creatinine>1.5mg/dl), (7.4% vs 33.3%, P=0.022), and critical limb ischemia (44.4% vs 
76.2%, P=0.027) at presentation. 
Eleven endovascular procedures were not technically successful and, 
subsequently, patients were submitted to ABF (n=6), axillobifemoral bypass (n=1), iliac 
stent with femorofemoral bypass (n=1) and best medical treatment (n=3). The mean 
Rutherford level at presentation was 3.3 and four patients had critical limb ischemia. 
The mean follow-up of these patients was 58 ±3.5months. 
The groups did not differ regarding limb salvage, infra-inguinal 
revascularization, first-month post-surgery ABI and long-term mortality (table 2). At 12 
months no differences were found in artery primary, assisted primary and secondary 
patency between approaches. The patency of procedures remained similar after 
adjusting for smoking habits (HR: 1.08 [0.206-5.47] P=0.925) and CHF (HR: 2.91 
[0.714-11.82], P=0.137). Although marginally significant, only ABF procedures were 
complicated by infection (11.1% vs 0%; P=0.053).  
 
Procedure Costs 
 
The mean direct costs in disposable material and equipment of the endovascular 
approach was significantly higher than that of the open surgery (1053±701€vs 1742+-
1386; P=0.001). However, patients undergoing the ABF procedure present a longer 
length-of-stay, spending significantly more time both in ward (9 vs 6 days; P=0.041) 
and in the ICU (3.81 vs 0 days; P=0.001). Therefore, the total cost of a patient, 
including procedure and admission, is significantly higher with open surgery (20.694+-
22346€ vs 10533+-12737€, P=0.001) (Table 2). The differences between groups 
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regarding the length of stay remained significant after splitting the analysis for the 
Rutherford subgroups: claudication and critical ischemia.  
Failed endovascular procedures had an equipment and material mean cost of 
1.193€ and a total mean cost of 12.192€. Therefore, taking in account all endovascular 
procedures, the technical failures imposed an increment of only 580€ to each successful 
intervention. 
Regarding re-intervention the angioplasty was the method of choice for the 
initial endovascular approach group and 5 (71%) of ABF patients. There were no 
differences regarding length-of-stay or costs of the second procedure (table 2).  
 
Quality of life Assessment 
 
After cross-sectionally applying the questionnaires, the endovascular approach 
group demonstrated a trend towards a higher global WIQ pain score (p=0.052) and 
statistically significant differences were found only in the question B3 (increased degree 
of difficulty walking 150 meters in the endovascular approach group) (p<0,001). The 
remaining domains (walking speed and climbing stairs) did not differ for global scores 
or individual questions (Table 3, Figure 4). The score in EQ-5D-5L questionnaire was 
not statistically different between groups individually or the index score (Table 3, 
Picture 5). 
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DISCUSSION 
 
The TASC type D AIOD standard of care remains controversial (1, 2). However, 
the morbidity (4, 5) and mortality (3) rates of open procedure are shifting the attention 
towards an “endovascular-first” approach even in complex lesions (8). In the present 
study, the technical and clinical success of the initial endovascular approach or open 
repair by means of ABF for TASC type D bilateral AIOD were compared. No 
significant differences were found regarding long-term patency despite a higher 
technical success of open surgery.  
The one-year patency, both crude and adjusted for smoking history, CHF and 
critical ischemia, did not differ between groups. These values fall below those reported 
by Kashyap et al (18) using patients with TASC type B or higher and those reviewed for 
TASC types C and D occlusive lesions (6). However, the rates here reported for ABF 
group were acceptable since only patients with TASC type D were included. The 
secondary patency rates were similar to the ones reported in the literature (6, 18). 
For percutaneous iliac stenting (PCIS), the primary patency for TASC D lesions 
in the literature varies between 70% to 97% at 12mo and 70.9% to 93% at 24mo (6, 9, 
10, 19-21). In the present study, although a different analysis was performed the 
primary patency at 12mo and 18mo was 82.2% and 69.1%, respectively. In this series, 
three factors (Smoking, CHF and CKD) were more prevalent in those who underwent 
an endovascular procedure technically succeeded when compared with those submitted 
to open surgery. These three factors are also related with loss of primary patency (4) 
which might contribute for the lower primary patency at 18 months. However, the cox-
regression analysis for CHF and critical ischemia did not demonstrate significant 
effects. The ABF group also presented values of patency below those reported in 
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literature which demonstrates that this series dealt with more severe and complex 
lesions as only TASC type D were included. In the present study, the secondary patency 
for the endovascular approach was 100% at 12 months which converges with previous 
reports (9, 10, 19, 20). These findings emphasize the paradigm shift towards an 
“endovascular-first” approach. Supporting this view is the fact that an open surgery can 
still be performed when the endovascular approach is not succeeded, seemingly without 
an increased risk of poor outcomes (11). In fact, it was reported an improved survival 
and a similar limb salvage rate for ABF after a failed endovascular attempt when 
compared with primary ABF procedure (11).  
Additionally, patients submitted to the endovascular approach were less 
frequently smokers, as verified in other studies (5, 18), and presented a significantly 
higher prevalence of CKD, CHF and critical ischemia at presentation, in the subgroup 
with technical success. Therefore, these patients were more fragile and prone to worse 
outcomes, severe lesions at presentation, major adverse limb events (4) and lower 
survival (18). The latter two variables reflect the atherosclerotic burden and were 
significantly impaired by the CHF, only present in the PCIS group due to a selection 
bias. Dyslipidemia and diabetes mellitus were not different in this series. The group 
submitted to ABF procedure had a mean age of 62 years, which favors the long-term 
patency; it was observed that patients <50 years old have less 30% of 5-year PP rate and 
less than 20% of 5-year SP rate when compared with patients >60 years old (22). This 
difference might reflect a more aggressive and progressive atherosclerotic process 
conditioning worse outcomes.  
 All ABF procedures were succeeded whereas only endovascular approach had a 
65.6% of technical success. The outcomes of endovascular treatment for extensive 
AIOD were previously addressed in a systematic review and technical success rates 
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were reported to be achieved in 86% to 100% of the patients (9). However, the review 
included both TASC type C and D lesions. For TASC type D lesions, the technical 
success is lower, ranging from 76.6% to 96.2%, with a mean of 90.1% (10). The lower 
technical success here presented might be explained by technical limitations, as most of 
the failures were early tries (8 out of 11 technical failures were before 2014).  
Concerning the surgery outcomes, the groups did not differ regarding limb 
salvage, infra-inguinal revascularization, post-surgery ABI and mortality. Of note, 
femoro-distal occlusive disease concomitant with iliac occlusion is a predictor for loss 
of PP in both procedures (5, 18, 23). The long-term mortality was not different between 
the techniques, in accordance with other reports (18 months - ABF: 81.9% SE=8.3% vs 
PCIS: 82% SE=7.3%) (4, 18, 24). 
Regarding the patient-reported QoL, this study demonstrated only minor 
differences. Despite the significantly higher comorbidities in the PCIS group, the EQ-
5D-5L questionnaire did not find any differences between groups. Comparing the 
disease-specific questionnaire, only minor significant changes were found in the 
claudication distance. This finding is compatible with the similar ABI that the patients 
presented in the first post-operative month. 
The mean direct cost of the endovascular approach is significantly higher than 
that of a conventional approach. In fact, an iliac stent costs three times more than an 
ABF graft (24). However, patients undergoing the ABF procedure presented 
significantly longer in-hospital time, in agreement with other reports (4, 5, 24-26), both 
in ward and ICU, being the later six-times more expensive. Therefore, the total costs of 
a patient, including procedure and admission, were significantly higher with open 
surgery. When the cost analysis was stratified according to the clinical peripheral artery 
disease staging (claudicants vs critical ischemia) the cost benefit remained present in 
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both categories. Moreover, endovascular technical failures only increased the total mean 
costs of each successful endovascular procedure in 580€. Since this study has low re-
intervention rates it was not possible to provide a reliable analysis of cost of re-
intervention. The few data available demonstrated similar costs, which were credible 
since the re-intervention strategy is the same (71% vs 100%, p=0.417). 
Despite the fact that previous studies found no difference between the costs of , 
of both procedures (25), recently endovascular approach was found to be less costly 
than the open procedure (24, 26). This shift of direction in the cost difference associated 
with the lower morbidity, mortality and length of stay of the endovascular technique has 
important implication as cost-containment policies are an ever-increasing theme of 
debate in healthcare policies. The indirect costs implied by prosthesis infection were not 
estimated although it would further increase the ABF procedure-related costs.   
This study has several limitations. First limitation was the lack of randomization 
for endovascular vs. open surgery selection, as the criteria was left to the surgeon’s 
discretion. Consequently, the endovascular group presented with a higher prevalence of 
comorbidities which could bias the QoL assessment and all the remaining endpoints. 
Another potential source of bias was the cross-sectional application of the QoL and 
disease-specific questionnaires, although the absence of significant differences in the 
follow-up period could mitigate the difference. Post-operative DALYs or the time 
needed to achieve peak post-operative QolL was not measured, although the ward and 
ICU days are a good post-operative morbidity indicator. Due to the severity of the 
lesions selected, this study presented a small sample although comparable with previous 
reports. 
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CONCLUSION 
 
To our best knowledge, this is the first study comparing the economic burden of 
these two approaches simultaneously with the post-surgical patients’ quality of life. 
Despite the higher rates of technical success in the open surgery group, the 
short-term patency and limb salvage of these procedures seem to be similar, as well as 
the post-operative patient referred Qol. Besides, the endovascular approach of the 
aortoiliac sector remains significantly less invasive imposing less perioperative 
morbidity, faster discharge, less disable days and less resource consumption. Moreover, 
execution of this procedure does not seem to negatively impact a future surgery, in case 
of technical failure, although more studies with longer follow-up are needed. 
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Tables 
 
Table 1 – Demographic and clinical data from patients undergoing revascularization for 
TASC D lesions. 
 
Variables 
ABF (n=27) Endovascul
ar approach 
(n=32) 
P 
value
* 
PCIS  ꝋ 
(n=21) 
pP value⸆ 
Age, years (mean ± 
SD) 
62.1 ± 6.5 65.6 ±12.2 0.173 65.0 ± 12.4 0.338 
Sex (male) 25 (92.6%) 29 (90.6%) 0.582 19 (90.5%) 0.594 
HTN 19 (70.4%) 17 (75%) 0.690 15 (71.4%) 0.936 
Smoking 27 (100%) 27 (75%) 0.050 15 (71.4%) 0.030 
CKD  2 (7.4%) 8 (25%) 0.073 7 (33.3%) 0.022 
DM 9 (33.6%) 9 (33.3%) 0.564 8 (38.1%) 0.732 
Dyslipidemia 17 (63%) 24 (75%) 0.317 15 (71.4%) 0.537 
CAD 6 (22.2%) 12 (37.5%) 0.204 7 (33.3%) 0.380 
CHF 0 10 (31.3%) 0.001 6 (28.6%) 0.030 
COPD 4 (14.8%) 5 (15.6%) 0.931 3 (14.3%) 0.959 
SFA disease 18 (66.7%) 22 (68.8%) 0.865 14 (66.7%) 1 
Critical ischemia  12 (44.4%) 21 (65.6%) 0.103 16 (76.2%) 0.027 
Rutherford 
Classification (mean) 
 
3.78 
 
4.06 
 
0.152 
 
4.18 
 
0.124 
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Claudication 
Rutherford 3 
Critical ischemia 
Rutherford 4 
Rutherford 5 
Rutherford 6 
 
14(51.9%) 
 
5 (18.5%) 
8 (29.6%) 
0 
 
11 (34.4%) 
 
11 (34.4%) 
7 (21.9%) 
3 (9.4%) 
 
5 (23.8%) 
 
9 (42.9%) 
5 (23.8%) 
2 (9.5%) 
Technical success 27 (100%) 21 (65.6%) 0.001   
 
ABF – aortobifemoral bypass grafting; CAD – Coronary Artery Disease; CHF – 
Chronic Heart Failure; CKD – Chronic kidney disease (creat>1.5mg/dl); COPD -  
Chronic Obstructive Pulmonary Disease; DM – Diabetes mellitus; HTN – 
Hypertension; PCIS– Percutaneous iliac stenting; SD – standard deviation; SFA disease 
– superficial femoral artery hemodynamically significant atherosclerotic disease. TASC 
D – TransAtlantic Inter-Society Consensus II (TASC II), iliac type D lesions  
 
ꝋ PCIS– Percutaneous iliac stenting – includes the patients from the endovascular 
approach group that were technically successful at first attempt. 
 
*Aortobifemoral bypass vs Endovascular approach 
⸆Aortobifemoral bypass vs Percutaneous Iliac stenting 
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Table 2 – Post-operative clinical factors, outcomes and costs of patients who underwent 
open surgery or endovascular approach* for iliac TASC D lesions. 
 
 ABF (n=27) 
Endovascular 
Approach (n=32) 
P value 
Follow-up (mean months±SD) 65.5± 3.9 48.2±5.1  0.689 
Infrainguinal Revascularization 6 (22.2%) 11 (34.4%) 0.352 
Ankle Brachial Index (mean) 0.79 ± 0.22 0.74 ± 0.23 0.383 
Primary patency  
12 months 
24 months 
 
85% (SE=6.9%) 
76.1% (SE=9%) 
 
82.2% (SE=7.3%) 
69.1% (SE=9.3%) 
 
0.584 
Assisted primary patency 
12 months 
 
85% (SE=6.9%) 
 
83.6% (SE=7.5%) 
 
0.709 
Secondary patency 
12 months 
 
92.3% (SE=5.2%) 
 
100% 
 
0.689 
Limb salvage 
          18 months 
 
(91.7%) (SE=8%) 
 
93.3% (SE=6.4%) 
 
0.645 
Mortality  
          18 months 
 
81.9% (SE= 8.3%) 
 
82% (SE= 7.3%) 
 
0.367 
Infection 3 (11.1%) 0 0.053 
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First procedure cost, €  (mean 
(SD)) 
   Claudicants 
    
   Critical ischemia 
    
   Total 
 
 
 
910 ± 614 
 
1160 ± 767 
 
1053±701 
 
 
1398 ±1019 
 
1954 ±1571 
 
1742±1386 
 
 
0.245 
 
0.122 
 
0.049 
Ward days (median - IQ) 
   Claudicants 
   Critical ischemia 
   Total 
 
6 [3-11]  
21 [10-24.75] 
9 [4-24] 
 
2 [0-8] 
10 [0-20] 
5 [2-11] 
 
0.62 
0.048 
0.09 
ICU, days (median - IQ) 
   Claudicants 
   Critical ischemia 
   Total 
 
3 [2-4] 
3 [2.25-4.75] 
3.81 3[2-4] 
 
0 [0-0] 
0 [0-0] 
0[0-0] 
 
0.02 
0.0 
0.0 
First intervention total costs, € 
(mean (SD))⸆ 
20694.5±22346 10533 ±12737 0.029 
Ward days in re-
intervention(Median - IQ) 
9.5 [1-14.25] 9 [1-14] 0.543 
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ICU days in re-intervention 
(Median - IQ) 
0[0-1] 2 [0-4] 0.151 
Re-intervention total costs, € 
(mean (SD))⸋ 
12338±5846 13929±11775 0.841 
Endovascular re-intervention 5 (71%) 8 (100%) 0.935 
ICU – intensive care unit; IQ – interquartile range; SD – standard deviation;  
 
*Endovascular approach includes patency after first failed revascularization and 
sucessfull second attempt. 
 
⸆ First intervention costs = First procedure cost + Length of stay (Mean ward days x 
537€ + ICU days x 2940€)  
⸋ Reintervention costs = Second procedure cost + Length of stay (Second intervention 
mean ward days x 537€ + Second intervention ICU days x 2940€) 
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Table 3 - Descriptive statistics of Peripheral Artery Disease and QoL questionnaires’ 
scores 
 
 ABF 
 
Endovascular 
approach 
P-value* 
WIQ Pain Score (0-24) 20.50 ±2.53 17.64±5.74 0.068 
WIQ Walking distance Score (0-100) 44.42 ±35.15 34.53±40.72 0.467 
WIQ Walking velocity Score (0-100) 31.70 ±18.50 34.29±30.53 0.773 
WIQ Climbing stairs Score (0-100) 68.75 ±30.91 60.71±33.56 0.487 
EQ-5D-5L B6 78% ±21.04 83%±12.5 0.889 
EQ-5D-5L Index⸋ 0,78 ±0.63 1.07±0.879 0.303 
All data are mean±standard deviation 
 
⸋ using EQ-5D-5L® formula 
 
WIQ – walking impairment questionnaire; EQ-5D-5L - 5-level EQ-5D 
version questionnaire  
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Figures 
 
Figure 1 – TASC D atherosclerotic lesions selected for the present study 
 
 
TASC D – TransAtlantic Inter-Society Consensus II (TASC II), iliac type D lesions  
Figure 2 – Kaplan-Meier curve estimates for patency according to treatment groups. 
 
Panel A: primary patency in patients undergoing aortobifemoral (ABF; blue line) 
bypass vs endovascular approach (green line). (logRank P=0.584).  
Panel B: assisted primary patency in patients undergoing aortobifemoral (ABF; blue 
line) bypass vs endovascular approach (green line). (logRank  P=0.709).  
Panel C: secondary patency in patients undergoing aortobifemoral (ABF; blue line) 
bypass vs endovascular approach (green line). (logRank P=0.689). 
 
   
 
   
 
 
 
ABF – Aortobifemoral bypass graft; Endovascular approach (Stenting and secondary 
open reinterventions) 
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Figure 3 – Histogram of Walking Impairment Questionnaire and EQ-5D-5L 
questionnaire results. 
 
 
 
 
 
 
 
 
WIQ – Walking Impairment Questionnaire; WIQ pain – Pain Score; WIQ Walking 
Velocity – Walking Velocity Score; WIQ Climbing Stairs – Climbing Stairs Score; 
EQ5D5L – Question 1, 2, 3, 4, 5; ABF – Aortobifemoral bypass graft; 
 
